In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing patient inclusion—while emphasizing the need for data quality, transparency, and trust to ensure responsible implementation.
AstraZeneca has partnered with Aptar to advance AI algorithms that can detect chronic kidney disease and related conditions through eye exams, aiming to improve early diagnosis and expand digital health capabilities in CKD management.
Pharmacists are uniquely positioned to improve patient safety and outcomes through behavior change counseling, using techniques like motivational interviewing to enhance medication adherence, empower self-management, and support lifestyle modifications.
In a new agreement announced by Cigna, its pharmacy unit Evernorth has partnered with Eli Lilly and Novo Nordisk to lower costs and cap monthly copays at $200 for GLP-1 weight loss drugs Wegovy and Zepbound, aiming to expand employer coverage while simplifying access and pre-authorization.
The FDA has ordered Pfizer and Moderna to expand label warnings on their COVID-19 vaccines due to updated data linking the shots to rare cases of heart inflammation—particularly in males ages 16 to 25—amid broader regulatory changes and growing scrutiny over vaccine safety.
